



## **Phase variable expression of capsular polysaccharide modifications allows *Campylobacter jejuni* to avoid bacteriophage infection in chickens**

Sørensen, Martine Camilla Holst; van Alphen, Lieke B. ; Fodor, Christopher; Crowley, Shauna M.; Christensen, Bjarke Bak; Szymanski, Christine M.; Brøndsted, Lone

*Published in:*  
Frontiers in Cellular and Infection Microbiology

*DOI:*  
[10.3389/fcimb.2012.00011](https://doi.org/10.3389/fcimb.2012.00011)

*Publication date:*  
2012

*Document version*  
Early version, also known as pre-print

*Citation for published version (APA):*  
Sørensen, M. C. H., van Alphen, L. B., Fodor, C., Crowley, S. M., Christensen, B. B., Szymanski, C. M., & Brøndsted, L. (2012). Phase variable expression of capsular polysaccharide modifications allows *Campylobacter jejuni* to avoid bacteriophage infection in chickens. *Frontiers in Cellular and Infection Microbiology*, 2, [11].  
<https://doi.org/10.3389/fcimb.2012.00011>



# Phase variable expression of capsular polysaccharide modifications allows *Campylobacter jejuni* to avoid bacteriophage infection in chickens

Martine C. Holst Sørensen<sup>1†</sup>, Lieke B. van Alphen<sup>2†</sup>, Christopher Fodor<sup>2</sup>, Shauna M. Crowley<sup>2</sup>, Bjarke Bak Christensen<sup>3</sup>, Christine M. Szymanski<sup>2\*</sup> and Lone Brøndsted<sup>1\*</sup>

<sup>1</sup> Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark

<sup>2</sup> Department of Biological Sciences, Alberta Glycomics Centre, University of Alberta, Edmonton, AB, Canada

<sup>3</sup> National Food Institute, Technical University of Denmark, Søborg, Denmark

## Edited by:

Alain Stintzi, Ottawa Institute of Systems Biology, Canada

## Reviewed by:

Jun Lin, The University of Tennessee, USA

Duncan Maskell, University of Cambridge, UK

## \*Correspondence:

Christine M. Szymanski, Department of Biological Sciences, Alberta Glycomics Centre, University of Alberta, Edmonton, AB, Canada T6G 2E9.

e-mail: christine.szymanski@ualberta.ca;

Lone Brøndsted, Department of Veterinary Disease Biology, University of Copenhagen, Stigbøjlen 4, DK-1879 Frederiksberg C, Denmark. e-mail: lbr@life.ku.dk

<sup>†</sup> Martine C. Holst Sørensen and Lieke B. van Alphen have contributed equally to this work.

Bacteriophages are estimated to be the most abundant entities on earth and can be found in every niche where their bacterial hosts reside. The initial interaction between phages and *Campylobacter jejuni*, a common colonizer of poultry intestines and a major source of food-borne bacterial gastroenteritis in humans, is not well understood. Recently, we isolated and characterized a phage F336 resistant variant of *C. jejuni* NCTC11168 called 11168R. Comparisons of 11168R with the wildtype lead to the identification of a novel phage receptor, the phase variable *O*-methyl phosphoramidate (MeOPN) moiety of the *C. jejuni* capsular polysaccharide (CPS). In this study we demonstrate that the 11168R strain has gained cross-resistance to four other phages in our collection (F198, F287, F303, and F326). The reduced plaquing efficiencies suggested that MeOPN is recognized as a receptor by several phages infecting *C. jejuni*. To further explore the role of CPS modifications in *C. jejuni* phage recognition and infectivity, we tested the ability of F198, F287, F303, F326, and F336 to infect different CPS variants of NCTC11168, including defined CPS mutants. These strains were characterized by high-resolution magic angle spinning NMR spectroscopy. We found that in addition to MeOPN, the phase variable 3-*O*-Me and 6-*O*-Me groups of the NCTC11168 CPS structure may influence the plaquing efficiencies of the phages. Furthermore, co-infection of chickens with both *C. jejuni* NCTC11168 and phage F336 resulted in selection of resistant *C. jejuni* bacteria, which either lack MeOPN or gain 6-*O*-Me groups on their surface, demonstrating that resistance can be acquired *in vivo*. In summary, we have shown that phase variable CPS structures modulate phage infectivity in *C. jejuni* and suggest that the constant phage predation in the avian gut selects for changes in these structures leading to a continuing phage–host co-evolution.

**Keywords:** bacteriophage, *Campylobacter jejuni*, capsular polysaccharide, phase variation, phosphoramidate, methylation

## INTRODUCTION

Bacteriophages (phages) are the most abundant group of organisms on the planet and are estimated to outnumber their bacterial hosts by 10-fold (Brüssow and Hendrix, 2002). The first step of phage infection is through the specific recognition and attachment of the phage particle to the host cell (Weinbauer, 2004). In general, phages bind to unique host-specific structures, thus allowing them to recognize a suitable host in a mixed bacterial population (Rakhuba et al., 2010). Knowledge of phage receptors is required for implementation of efficient phage therapies against human pathogens – an intervention strategy that has been

promoted by the increasing occurrence of antibiotic resistance (Levy and Marshall, 2004; Kutateladze and Adamia, 2010), yet only a few bacterial phage receptors have been identified in Gram-negative bacteria (for example, Gemski and Stocker, 1967; Stirm and Freund-Molbert, 1971; Gemski et al., 1975; Yu and Mizushima, 1982; Morona et al., 1984).

Capsular polysaccharides (CPS) are highly hydrated polymeric gels that provide a thick (400 nm or more) layer protecting bacteria from hostile environments and host immune defenses, but the CPS can also be a target for phage binding and infection (Stirm and Freund-Molbert, 1971; Roberts, 1996; Comstock and Kasper, 2006). The capsule of the zoonotic foodborne pathogen, *Campylobacter jejuni*, is required for serum resistance, invasion of human epithelial cells, colonization of chickens, and diarrheal disease in ferrets (Bacon et al., 2001; Jones et al., 2004). Furthermore, mutation of several *C. jejuni* CPS genes resulted in phage resistance against a group of phages, but the actual capsular moieties involved

**Abbreviations:**  $\beta$ -D-Rib, ribose;  $\beta$ -D-Gal/NAc, *N*-acetylgalactosamine in the furanose configuration;  $\alpha$ -D-GlcA6(NGro), glucuronic acid with 2-amino-2-deoxyglycerol at C-6; MeOPN, *O*-methyl phosphoramidate; Hepp, heptose. The 2-amino-2-deoxyglycerol can also be substituted with an *N*-ethanolamine modification at C-6.

were not identified (Coward et al., 2006). Only recently a specific component of the *C. jejuni* capsule was identified as the phage receptor for this species. We showed that phage F336 relies on the *O*-methyl phosphoramidate (MeOPN) modification of the *C. jejuni* NCTC11168 CPS for adsorption to the host cell surface and infection (Sørensen et al., 2011).

The CPS of *C. jejuni* is the major component recognized by the Penner serotyping scheme for which 47 different serotypes are known (Guerry et al., 2012). Thus, the CPS are highly diverse in structure and this is reflected by the gene content of the capsular loci in various *C. jejuni* strains (Karlyshev et al., 2005). In addition, a number of CPS genes possess homopolymeric tracts making them prone to phase variation which allows a rapid on/off switching of the genes and promotes variations in CPS even when the strains have identical gene contents (Linton et al., 2001; St Michael et al., 2002; Karlyshev et al., 2005; McNally et al., 2005; Chen et al., 2008). The CPS of *C. jejuni* 11168 consists of -2)- $\beta$ -D-Ribf-(1-5)-3-MeOPN- $\beta$ -D-GalNAc-(1-4)- $\alpha$ -D-GlcpA6(NGro)-(1-backbone with a 3,6-di-*O*-methyl-4-MeOPN-D-glycero- $\alpha$ -L-gluco-Hep side chain (St Michael et al., 2002; Szymanski et al., 2003; McNally et al., 2005). The CPS biosynthetic locus in strain NCTC11168 includes 28 genes and 6 of these genes (*cj1420*, *cj1421*, *cj1422*, *cj1426*, *cj1429*, and *cj1437*) contain homopolymeric G (polyG) tracts (Parkhill et al., 2000). Even though the function of only three out of the six gene products has been identified, a highly variable presence/absence of methyl, ethanolamine, aminoglycerol, and phosphoramidate modifications of the CPS have been observed (St Michael et al., 2002; Szymanski et al., 2003; McNally et al., 2005), suggesting that the remaining genes could encode enzymes involved in synthesis or transfer of these modifications to the CPS glycans. Recently, the *cj1421* and *cj1422* genes were shown to encode

MeOPN transferases attaching MeOPN to the GalNAc and the Hep residues, respectively (McNally et al., 2007). Similarly, *cj1426* was demonstrated to encode the 6-*O*-Me transferase enzyme (Sternberg et al., submitted).

We previously discovered that resistance toward phage F336 evolved with a high frequency in *C. jejuni* NCTC11168 due to loss of the MeOPN receptor on the bacterial surface as a result of phase variation in the *cj1421* gene encoding the MeOPN–GalNAc transferase. In addition, deletion of the *cj1421* gene in NCTC11168 resulted in phage resistance, proving that MeOPN attached to GalNAc was a receptor for phage F336 (Sørensen et al., 2011). The aim of the present study was to determine if other phages rely on the MeOPN moiety for infection of *C. jejuni* and to explore the role of other CPS phase variable modifications for phage infection. Knowledge of phage receptors and development of phage resistance *in vivo* is essential for implementation of efficient phage therapy against *C. jejuni* in the chicken gut. We found that not only the MeOPN moiety, but also the phase variable 3-*O*-Me and 6-*O*-Me groups in the CPS of *C. jejuni* NCTC11168 may influence phage sensitivity. Co-infection of chickens with *C. jejuni* NCTC11168 and phage F336 resulted in bacterial acquisition of phage resistance through a loss of MeOPN attached to GalNAc of the capsule or the acquisition of the 6-*O*-Me group. We propose that the constant exposure of *C. jejuni* to naturally occurring phages in the avian gut selects for different phase variable structures of the CPS resulting in a continuous phage-host co-evolution.

## MATERIALS AND METHODS

### BACTERIAL STRAINS, MEDIA, AND GROWTH CONDITIONS

The *C. jejuni* strains used in this study are listed in **Table 1** and were routinely grown on blood agar Base II (Oxoid) supplemented

**Table 1 | *Campylobacter jejuni* strains.**

	Serotype	Description	Reference
1447	HS:4c	Chicken isolate	Hansen et al. (2007)
NCTC12662	HS:5j	Origin not known	National Collection of Type Cultures, UK
NCTC11168 (MP21)	HS:2	Wild type	Sørensen et al. (2011)
NCTC11168 MP24	HS:2	NCTC11168 variant passaged	This study
NCTC11168 MP25	HS:2	NCTC11168 variant passaged	This study
NCTC11168 MP26	HS:2	NCTC11168 variant passaged	This study
NCTC11168 V26	HS:2	NCTC11168 variant	Carrillo et al. (2004)
<i>kpsM</i>	Untypeable	NCTC11168 <i>kpsM::kan</i> does not have a capsule	Karlyshev et al. (2000)
11168R		Phage F336 resistant NCTC11168	Sørensen et al. (2011)
S11168R		Phage-sensitive 11168R	Sørensen et al. (2011)
11168H	HS:2	Hypermotile NCTC11168	Jones et al. (2004)
11168H $\Delta$ 1421		Loss of MeOPN on GalNAc	McNally et al. (2007)
11168H $\Delta$ 1421/1422		Loss of MeOPN on GalNAc	McNally et al. (2007)
		Loss of MeOPN on Hep	
11168H $\Delta$ 1422		Loss of MeOPN on Hep	McNally et al. (2007)
11168H $\Delta$ 1421/1422 + 1422		Loss of MeOPN on GalNAc	McNally et al., 2007
		Gain of MeOPN on Hep	
11168H1		11168H variant	This study
		Loss of 6- <i>O</i> -Me and MeOPN on Hep	

**Table 2 | Bacteriophages.**

	Category <sup>a</sup>	HhaI restriction pattern <sup>b</sup>	Origin	Reference
F198	III	c	Broiler intestine	Hansen et al. (2007)
F287	III	d	Duck intestine	Hansen et al. (2007)
F303	III	d	Duck abattoir	Hansen et al. (2007)
F326	III	d	Duck intestine	Hansen et al. (2007)
F336	III	b	Duck intestine	Hansen et al. (2007)

<sup>a</sup>Category is based on genome size (all are 140 kb) as defined in Sails et al. (1998).

<sup>b</sup>HhaI restriction pattern as determined in Hansen et al. (2007) b, 5 + 2 weak bands; c, 4 bands; d, 3 bands.

with 5% calf blood (BA) or in brain heart infusion (BHI) broth under microaerobic conditions (6% CO<sub>2</sub>, 6% O<sub>2</sub>, 84% N<sub>2</sub>, and 4% H<sub>2</sub>) at 37°C. For chicken experiments, bacteria were grown on Karmali agar (Oxoid) supplemented with *Campylobacter* selective supplement under microaerobic conditions (10% CO<sub>2</sub>, 5% O<sub>2</sub>, 85% N<sub>2</sub>) at 37°C.

### BACTERIOPHAGES

Bacteriophages used in this study are listed in **Table 2**. They all belong to the family of Myoviridae and have genome sizes of approximately 140 kb, but show different *HhaI* restriction patterns. Phages were propagated on *C. jejuni* NCTC12662, except for phage F336 where *C. jejuni* 1447 was used (Hansen et al., 2007). Stock bacteriophages were kept in SM buffer (0.05 M Tris–Cl, pH 7.5 supplemented with 5.8 g NaCl, 2.0 g MgSO<sub>4</sub>·7H<sub>2</sub>O, and 5 ml gelatin, 2% w/v solution) at 4°C.

### BACTERIOPHAGE PROPAGATION

Bacteriophage propagation was performed as described by Sørensen et al. (2011) using a plate lysis method developed from Frost et al. (1999), Hansen et al. (2007). The propagating strains were grown overnight on blood agar Base II plates and harvested in BHI supplemented with 1 mM CaCl<sub>2</sub> and 10 mM MgSO<sub>4</sub> (CBHI). Bacterial suspensions were adjusted to an optical density of OD<sub>600</sub> = 0.35, incubated for 4 h at 37°C under microaerobic conditions, mixed with phages at a multiplicity of infection (MOI) of 0.01 and incubated for 15 min at 37°C to allow bacteriophage adsorption. Subsequently, 0.6 ml of the adsorbed suspensions were mixed with 5 ml of NZCYM overlay agar [NZCYM (Sigma) broth with 0.6% agar] at 45°C and poured onto NZCYM 1.2% agar plates. After incubation, plates with lysis were flooded with sterile SM buffer and the phages eluted overnight with gentle shaking at 4°C. Phage suspensions were harvested and filtered through a sterile 0.2 µm membrane filter.

### BACTERIOPHAGE TITRATION

Bacteriophage titration was performed as previously described (Sørensen et al., 2011). Briefly, bacterial lawns were made by mixing 5 ml NZCYM overlay agar tempered at 45°C with 0.5 ml bacteria harvested in CBHI from Base II agar plates and incubated for 4 h as described above and poured onto NZCYM plates. Phage solutions were spotted manually with three times 10 µl of

10<sup>0</sup>–10<sup>–7</sup> phage dilutions in SM buffer. Plates were incubated at 37°C for 20–24 h under microaerobic conditions and the number of plaque-forming units per milliliter (PFU/ml) of undiluted phage suspensions was calculated. Usually, phage titers of 10<sup>8</sup>–10<sup>9</sup> PFU/ml could be obtained on both the propagating strains and *C. jejuni* MP21.

### PLAQUE ASSAY

Susceptibility of a *C. jejuni* strain to the bacteriophages was performed using the plaque assay protocol described under Bacteriophage titration and determined as the efficiency of plaquing (EOP) in percent by dividing the PFU/ml on the test strain by the PFU/ml on the control strain (NCTC11168) multiplied by 100. The values represented are the mean count standard deviations derived from two to four independent experiments.

### HIGH-RESOLUTION MAGIC ANGLE SPINNING NMR SPECTROSCOPY

High-resolution magic angle spinning (HR-MAS) NMR analysis of intact bacterial cells was performed as previously described (McNally et al., 2005).

### IN VIVO EXPERIMENTS

One-day-old chickens were obtained from the Poultry Research Facility, Department of Agriculture, Food and Nutritional Science, University of Alberta. On the day of arrival, chickens were checked for *C. jejuni* colonization by cloacal swabs and divided in groups of four chickens. On day 2, chickens were first orally gavaged with either 10<sup>7</sup> F336 phages in SM buffer or with SM buffer alone. After approximately 30 min, the chickens were orally gavaged with a suspension containing 10<sup>6</sup> *C. jejuni* NCTC11168 in PBS or with PBS alone. Six days post infection, chickens were euthanized and the contents from one cecum were collected aseptically. The cecal contents were weighed and resuspended in phosphate-buffered saline at a final concentration of 0.1 g/ml. This suspension was subjected to 10-fold serial dilutions and plated onto Karmali selective agar plates to determine bacterial colonization levels. One hundred microliters of the 10<sup>–1</sup> dilution was plated separately onto selective plates and all resulting bacterial colonies were pooled together. Half of this pool was used for sequencing and phage sensitivity and the other half was used for NMR analysis. The experiment was repeated twice with consistent results. PCR of gene *cj1421* was performed as previously described (Sørensen et al., 2011) while sequencing was done using the following primer: 1421-seq2-F (5'-CTCGAGTTATAAGGATATTTTAGATGAG-3'). Gene *cj1426* was PCR-amplified using the primers: 1426-PCR-F (5'-TTGAGAATTATGATAAGATGAAGG-3') and 1426-PCR-R (5'-TTTCTAAGAATTCTTTACTTTTCG-3') and then sequenced using the primers: 1426-seq-F (5'-AAGATCCAGATAAAAGAGAT TATTTGG-3') and 1426-seq-R (5'-ATCAGGAGAATCAAAAA TGATTTTTC-3').

## RESULTS

### THE MeOPN MOIETY OF THE CPS OF *C. jejuni* NCTC11168 IS A RECEPTOR FOR SEVERAL PHAGES

We recently demonstrated that phage F336 requires the *O*-methyl phosphoramidate (MeOPN) moiety attached to the Gal/Nac of the *C. jejuni* NCTC11168 CPS for infection (Sørensen et al., 2011).

**Table 3 | Efficiency of plaquing (EOP) of phages related to F336 as compared to NCTC11168.**

Phage	NCTC11168	11168R	S11168R	<i>kpsM</i>
F198	100 <sup>a</sup>	— <sup>b</sup>	82.5 ± 24.7	—
F287	100	0.04 ± 0.03	2300 ± 282.8	—
F303	100	—	350 ± 113.1	—
F326	100	0.02 ± 0.02	11.6 ± 6.7	—
F336	100	—	331.8 ± 64.3	—

<sup>a</sup>EOP is calculated in percent as the PFU/ml of the phages on the test strain divided by the PFU/ml obtained on NCTC11168 multiplied by 100.

<sup>b</sup>—No plaques formed.

In our phage collection (Hansen et al., 2007) we found that five phages, including F336, rely on capsular moieties for infection of *C. jejuni* NCTC11168, since they do not form plaques on a *kpsM* capsule mutant (Table 3). In our previous study, we isolated a phage F336 resistant NCTC11168 variant *in vitro* (11168R), which lost the MeOPN attached to the Gal/Nac residue due to the presence of an additional G in gene *cj1421* resulting in an off version of the gene (Sørensen et al., 2011). Here we found that 11168R had gained cross-resistance to all of the four phages: F198, F287, F303, and F326 (Table 3). While phages F198 and F303 did not form plaques on *C. jejuni* 11168R at all, plaques were observed with F287 and F326, but with a much lower EOP compared to wild type NCTC11168. Hence, the MeOPN structure is important for infection by the four other phages, although two of these phages (F287 and F326) were able to infect a strain not expressing the MeOPN modification. Similar results were obtained when screening a *cj1421* MeOPN transferase deletion mutant in the NCTC11168 wild type background (data not shown). Supporting this, the EOP of four of these phages, including F336, were fully restored to wild type NCTC11168 levels, while the EOP of phage F326 was partially restored, when we tested the phages against a 11168R revertant containing an intact *cj1421* gene and returned expression of the CPS MeOPN (*C. jejuni* S11168R; Sørensen et al., 2011; Table 3). Thus, several phages rely on the MeOPN moiety attached to the Gal/Nac residue of CPS for infection of *C. jejuni* NCTC11168.

#### THE LOCATION OF THE MeOPN ON THE CPS IS IMPORTANT FOR PHAGE INFECTION

The MeOPN moiety of *C. jejuni* NCTC11168 can be attached to the Gal/Nac and the Hep residues in the CPS (McNally et al., 2007) and we speculated that the attachment site of MeOPN may be important for phage infection. We therefore conducted plaque assays and determined EOPs of the five phages F198, F287, F303, F326, and F336 on the hypermotile NCTC11168 variant 11168H as well as on defined mutants in the *cj1421* and *cj1422* MeOPN transferase genes in this background and compared to the NCTC11168 wild type strain. All of these strains have previously been characterized by HR-MAS NMR and <sup>1</sup>H–<sup>31</sup>P heteronuclear single-quantum correlation (HSQC) HR-MAS NMR for the presence/absence of MeOPN in their CPS structure (McNally et al., 2007). Our results showed that the attachment site of MeOPN in the CPS clearly influenced the efficiency of the phages to infect a particular strain

(Figure 1). In general, all phages showed a higher EOP when MeOPN was situated on the Gal/Nac residue (Figures 1A,E) as compared to MeOPN attached to the Hep residue in the CPS (Figure 1C). A lower EOP obtained with MeOPN attached to the Hep residue was further confirmed by screening a *cj1421* + *cj1422* deletion strain complemented with *cj1422* (McNally et al., 2007) with our five phages (Figure 1F). Interestingly, the four phages F198, F287, F303, and F336 were not able to infect *C. jejuni* 11168H, which is the only strain expressing MeOPN on both Gal/Nac and Hep (Figure 1B), suggesting that two MeOPN moieties may inhibit phage infection. Finally, we observed that the presence of two other phase variable CPS modifications, the 3-O-Me and 6-O-Me groups influenced the plaquing efficiency of the phages. We also isolated a 11168H single colony variant (11168H1) that by HR-MAS NMR and <sup>1</sup>H–<sup>31</sup>P HSQC HR-MAS NMR analysis showed the same CPS profile as the NCTC11168 wild type strain (data not shown). The phage sensitivity profile observed with this strain (Figure 1G) confirmed the results obtained with NCTC11168 (Figure 1A). Thus, the presence of the 6-O-Me group on the CPS reduced the plaquing efficiencies of phages F287 and F326 (Figures 1A,E), suggesting that other phase variable CPS modifications besides MeOPN affect phage infection.


#### *C. jejuni* PHAGES REQUIRE DIFFERENT COMBINATIONS OF PHASE VARIABLE CPS MODIFICATIONS FOR SUCCESSFUL INFECTION

Phase variable expression of the capsular modifications in *C. jejuni* NCTC11168 is well documented (Parkhill et al., 2000; St Michael et al., 2002; Szymanski et al., 2003). Three frozen stocks of NCTC11168 (MP24, MP25, and MP26) that had been passaged a number of times in our laboratory were analyzed by HR-MAS NMR and <sup>1</sup>H–<sup>31</sup>P HSQC HR-MAS NMR (Figure 2). This analysis revealed differences in the four phase variable modifications of the CPS structure, i.e., the 3-O-Me, 6-O-Me, MeOPN-Gal/Nac, and MeOPN-Hep as compared to our NCTC11168 wild type (Table 4). We also included another NCTC11168 variant (V26) previously shown to have yet another different set of modifications (St Michael et al., 2002; Carrillo et al., 2004).

Plaque assays using our five phages showed that these *C. jejuni* strains had distinct phage sensitivity profiles (Figures 3B–E). Interestingly, *C. jejuni* MP26 that expresses both MeOPN moieties, similar to the phage-resistant *C. jejuni* 11168H (Figure 1B), could be infected by four of the five phages although with different efficiencies (Figure 3D). However, CPS of *C. jejuni* MP26 only contains the 3-O-Me group, whereas 11168H CPS contains both the 3-O-Me and 6-O-Me groups (Figures 1B and 3D). These results indicate that the presence of 6-O-Me may inhibit phage infection. This was further supported by the observation that none of the phages formed plaques when the 3-O-Me was exchanged with the 6-O-Me while retaining the MeOPN modification attached to Gal/Nac (Figures 3A,E). Furthermore, the presence of the 6-O-Me group in combination with a MeOPN situated on the Gal/Nac and a 3-O-Me group clearly inhibited infection by phage F287 and F326 (Figures 1E,G). Thus, our data suggest that the 6-O-Me group inhibits plaque formation *in vitro* and that all five phages require MeOPN attached to Gal/Nac together with the 3-O-Me to obtain the most efficient infection. However, different combinations of the phase variable CPS modifications appear to influence







**FIGURE 2 | High-resolution magic angle spinning NMR spectra showing the differences in CPS modifications between NCTC11168 variants MP24, MP25 and MP26. <sup>1</sup>H CPMG spectra of intact *C. jejuni* cells. Abbreviations**

are: Hep, D-glycero- $\alpha$ -L-gluco-Hep; Rib,  $\beta$ -D-Ribf; GlcA,  $\alpha$ -D-GlcA6(NGro); GalfNAc,  $\beta$ -D-GalfNAc; MeOPN, O-methyl phosphoramidate; OMe, O-methyl; NAc, N-acetyl; TSP, trimethylsilyl propionic acid standard.

**Table 4 | ppm Values for <sup>1</sup>H HR-MAS NMR spectra for NCTC11168 variants and MeOPN transferase status.**

<i>C. jejuni</i> strain	Hep <sup>a</sup>	Rib	GlcA	GalfNAc	3-O-Me	6-O-Me	NAc	MeOPN	<i>cj1421/cj1422</i> (GalfNAc/Hep) <sup>b</sup>
NCTC11168 MP24	5.582	5.376	5.103	5.015	3.629	3.557	2.071	3.772	-/+
NCTC11168 MP25	5.599	5.363	5.148	5.039	–	3.569	2.066	– (3.772) <sup>c</sup>	-/-
NCTC11168 MP26	5.610	5.361	5.143	5.101	3.630	–	2.068	3.768/3.743	+/+

<sup>a</sup> Only anomeric proton resonances for carbohydrate residues are listed.


<sup>b</sup> Summary of sequencing results indicating the “on” (+) and “off” (–) status of the genes encoding the MeOPN transferases onto GalfNAc (*cj1421*) and Hep (*cj1422*).

<sup>c</sup> Only trace amounts of MeOPN detected.

MeOPN in all instances, except for one (Figure 4; Table 5). In chicken #238, infected with phage F336 and *C. jejuni*, the bacteria showed reduced levels of MeOPN present on both GalfNAc and Hep, but the bacteria also expressed high levels of 6-O-Me on the Hep (Figure 4).

To test whether the observed changes in CPS modifications resulted in phage resistance, we performed bacterial titration assays with all of the isolates recovered from the chickens. All isolates from the F336 infected birds had gained resistance to phage F336 and still showed similar levels of colonization (Table 5). Previously, we have shown that a loss of MeOPN on GalfNAc can be the result of a switch in the polyG region of the MeOPN transferase gene *cj1421* (Sørensen et al., 2011). To determine whether the loss of MeOPN and subsequent phage resistance were the result

of a switch in the polyG region, we sequenced gene *cj1421* from the pooled colonies from both experiments. All phage-sensitive isolates showed 9 G residues in the polyG region, while all phage-resistant isolates (except from chick 238) showed either 8 or 10 G residues in this region, which in both cases results in a non-functional transferase, due to a premature stop codon 1 or 5 amino acids after the polyG region, respectively (data not shown). Examination of the pooled colonies from chick 238 showed 9 G residues in the polyG region of *cj1421*, consistent with the observed MeOPN expression. However, sequencing of the polyG region of *cj1426* from the pooled colonies from chick 238 showed 10 G residues indicating that the 6-O-Me transferase enzyme was functional (again consistent with the acquired expression of the Me modification in Figure 4) compared to 11 G residues in



**FIGURE 3 | Capsular polysaccharide structures expressed by NCTC11168 variants and the corresponding phage sensitivity profiles.** The CPS structure is schematically illustrated (modified from Guerry and Szymanski, 2008). Phage sensitivity patterns are calculated as the 'efficiency of plaquing (EOP) as compared to plaque formation on the NCTC11168 wild type strain.

(A) NCTC11168; (B) NCTC11168 MP24; (C) NCTC11168 MP25; (D) NCTC11168 MP26; and (E) NCTC11168 V26. <sup>1</sup>MeOPN only detected in minor amounts. Abbreviations as above are: GalNAc, *N*-acetylgalactosamine in the furanose configuration; MeOPN, *O*-methyl phosphoramidate; Hep, heptose; and *O*-Me, *O*-methyl.

the parental strain lacking this modification. Thus, *C. jejuni* can become resistant to phage F336 during *in vivo* colonization of chickens by changing the expression of its CPS phase variable modifications.

## DISCUSSION

Implementation of efficient phage therapies to target pathogenic bacteria requires detailed knowledge of the bacterial receptors recognized by the phages, as this bacteria–phage interaction is the first event in a process leading to lysis of the host organism. We previously identified the *C. jejuni* NCTC11168 CPS phase variable MeOPN modification as the receptor for phage F336 (Sørensen et al., 2011). The goal of the present study was to further explore the role of MeOPN and other *C. jejuni* phase variable CPS modifications, such as *O*-methylation in phage infection. We compared five different phages, including F336 that were unable to proliferate in an acapsular mutant of *C. jejuni* NCTC11168, and determined their ability to infect NCTC11168 variants containing the same CPS backbone sugars as NCTC11168, but with different modifications.

We found that the phages F198, F287, F303, F326, and F336 all infected *C. jejuni* most efficiently when the 3-*O*-Me modification on Hep and a MeOPN moiety was present, with higher EOPs observed when the MeOPN modification was attached to GalNAc rather than Hep. Interestingly, when the 3-*O*-Me was exchanged with the 6-*O*-Me while retaining the MeOPN on GalNAc, none of the phages formed plaques at all, demonstrating a clear role for the *O*-methyl Hep modifications for phage infection, in addition to the previously identified phage receptor, MeOPN (Sørensen et al., 2011). By looking at the predicted three dimensional (3D) structure of the *C. jejuni* NCTC11168 CPS (Guerry and Szymanski, 2008), it is possible that the presence or absence of one or more CPS modifications may lead to conformational changes that interfere with the phage binding process. Indeed it has been found that changes in the 3D conformation of the outer membrane protein OmpA, which serves as the receptor for many of the T-even phages infecting *E. coli*, leads to phage resistance (Riede and Eschbach, 1986). Furthermore, the spatial arrangement of the modifications may be important for phage recognition and some modifications may potentially block the phage binding site when



**Table 5 | Presence of MeOPN and phage sensitivity of *C. jejuni* isolated after colonization of chickens.**

	Infected with	Bacterial counts (CFU/g)	MeOPN on Gal/Nac	Phage sensitivity <sup>a</sup>
MP21 Inoculum	NR	NR	+	Yes
MP21 Karmali	NR	NR	+	Yes
Chick 405	MP21	$5.7 \times 10^9$	+	Yes
Chick 406	MP21	$4.1 \times 10^9$	+	Yes
Chick 407	MP21	$9.9 \times 10^8$	+	Yes
Chick 408	MP21	$1.1 \times 10^9$	+	Yes
Chick 505	MP21 + F336	$7.9 \times 10^8$	–	No
Chick 506	MP21 + F336	$5.0 \times 10^9$	–	No
Chick 507	MP21 + F336	$5.8 \times 10^9$	–	No
Chick 508	MP21 + F336	$8.5 \times 10^8$	–	No
Chick 343	MP21	$2.0 \times 10^9$	+	Yes
Chick 344	MP21	$2.1 \times 10^9$	+	Yes
Chick 345	MP21	$1.6 \times 10^9$	+	Yes
Chick 346	MP21	$3.6 \times 10^9$	+	Yes
Chick 237	MP21 + F336	$1.2 \times 10^9$	–	No
Chick 238	MP21 + F336	$5.5 \times 10^9$	+ <sup>b</sup>	No
Chick 239	MP21 + F336	$4.7 \times 10^9$	– <sup>c</sup>	No
Chick 240	MP21 + F336	$4.1 \times 10^9$	–	No

Chicks 405–408 and 505–508 are from the first experiment, while chicks 343–346 and 237–240 are from the second experiment.

<sup>a</sup>Yes: plaques formed on isolated strain, No: no plaques formed on isolated strain.

<sup>b</sup>Bacteria isolated from this chick showed reduced MeOPN levels (of both MeOPN groups) and enhanced levels of 6-O-Me.

<sup>c</sup>MeOPN levels barely above the baseline could be detected from bacteria isolated from this chick.


NR, not relevant.

they are expressed. Certainly masking the phage binding site is a well known resistance mechanism in other bacteria. One example is *Staphylococcus aureus* that masks its phage receptor with protein A, a cell-wall-anchored virulence factor for this bacterium (Nordstrom and Forsgren, 1974). In agreement with this hypothesis, we observed that when MeOPN was present on both the Gal/Nac and Hep residues together with the 3-O-Me and 6-O-Me Hep modifications, then four of the five phages could no longer infect that particular *C. jejuni* 11168 strain. Thus, both the presence and absence of the capsular modifications appears to modulate phage infectivity of the NCTC1168 strain.

Our results demonstrate that the phages infecting *C. jejuni* are highly specific in the recognition of the CPS and that each phage has evolved to recognize a particular combination of capsular modifications. One might speculate that the phages included in this study originated from the same ancestral phage that has co-evolved with *C. jejuni* to recognize different capsular surface structures by minor modifications in the phage receptor binding proteins (RBP). In support of this, sequencing of viral proteins from the *C. jejuni* phage CP220 revealed at least two distinct tail structures in the mature virions although propagated from a single plaque (Timms et al., 2010), suggesting a possibility for the phage to recognize multiple receptors. A similar phenomena has been observed for capsular phages infecting *E. coli* (Scholl et al., 2001). Indeed RBPs of other phages often have hypervariable regions in the receptor recognizing domains, reflecting the ability of the phage to easily accumulate mutations thereby changing the structure of the RBP to recognize modified receptors or new types of

receptors, such as switching from protein to carbohydrate recognition (Montag et al., 1990; Drexler et al., 1991; Hashemolhosseini et al., 1994). The *C. jejuni* phages investigated in this study have similar genome sizes and morphologies and were previously isolated from duck and broiler intestines and duck abattoirs (Hansen et al., 2007). Although these phages all are able to infect the NCTC1168 strain, they do show different host ranges for *C. jejuni* strains of different Penner serotypes (Hansen et al., 2007). In addition, enzymatic restriction cleavage of the phage genomes revealed differences among the phages (Table 2, Hansen et al., 2007). Thus, although a conserved head and tail architecture is maintained, it is apparent that genomic dissimilarities exist between the five phages compared in this study and this may account for the differences in host specificity.

In *C. jejuni*, the CPS are highly diverse, due to differences in the genetic compositions of the CPS loci, but also because many of the genes in these loci contain homopolymeric tracts making them prone to phase variation (Linton et al., 2001; St Michael et al., 2002; Szymanski et al., 2003; Karlyshev et al., 2005; McNally et al., 2005; Chen et al., 2008). Based on the number of phase variable modifications in the capsule of *C. jejuni* NCTC1168 alone, this may result in the expression of >700 CPS structural variants. Our results demonstrate that phase variable CPS surface structures clearly influence the phage attachments sites in *C. jejuni* NCTC1168. Phase variable expression also affects phage adsorption in *Bordetella* spp. These bacteria use phase variable expression of the BvgAS two-component regulatory system to alter their surfaces through the regulation of colonization and virulence factors



**FIGURE 4 | NMR analysis of intact *C. jejuni* cells recovered from chicken cecal contents. (A)**  $^1\text{H}$  HR-MAS NMR CPMG spectra, displaying the capsular profile and **(B)** corresponding 1D  $^1\text{H}$ - $^{31}\text{P}$  HSQC spectra specifically

demonstrating the phosphoramidate resonances. Black arrowhead: note the change in the Gal/Nac resonance due to the absence of MeOPN. White arrowhead: note the absence of the MeOPN specific resonance.

and also expression of the phage BPP-1 receptor Prn (pertactin autotransporter; Liu et al., 2002). To combat these changes, the BPP-1 phage has a sophisticated mechanism of varying its RBP ( $\sim 10^{+13}$  possible sequences) that approaches the levels of diversity observed for immunoglobulins (Liu et al., 2002; Doulatov et al., 2004), and the phage is thus able to overcome the resistance by an equally efficient mechanism.

It was previously shown that CPS expression is important for *C. jejuni* colonization of the chicken gut as well as being important for interactions with human models of disease (Bacon et al., 2001; Jones et al., 2004). Here we show for the first time that the presence of phages selects for specific CPS variants *in vivo* in the chicken gut without altering the colonization levels, even though MeOPN expression influences *C. jejuni* invasion of human cells (van Alphen, unpublished results). Thus, the roles of phase variable CPS modifications, such as the MeOPN and the O-methyl groups, may not only be linked to adaptation to the human or chicken hosts, but may serve an important function for *C. jejuni* survival in the avian gut; an environment that contains a high number of bacteria as well as phages (Connerton et al., 2004; Hansen et al., 2007). Scott et al. (2007) also described that certain isolates of *C. jejuni* containing Mu-like prophage DNA sequences were capable of developing bacteriophage resistance in the chicken gut through a mechanism of reversible genomic rearrangement. Remarkably, these isolates inverted genomic segments up to 590 kb which also led to a decrease in chicken colonization and production of a functional Mu-like bacteriophage (Scott et al., 2007). The authors speculated that the development of phage resistance could be due to alterations in the bacterial surface receptor or

through saturation of the receptor sites if the Mu phage is recognizing the same structures. Here, we have shown that phase variable modifications of the CPS influence phage infectivity, suggesting that the constant exposure of *C. jejuni* to phages in the avian gut selects for changes in the phase variable structures of the CPS leading to a continuing co-evolution of *C. jejuni* polysaccharides and phage RBPs. This should be considered when developing future strategies for phage therapy against *C. jejuni* in the chicken host and when determining the kinetics of resistance development and the timing for therapy administration. Since the alteration of bacterial surface receptors that reduces or eliminates phage adsorption to the host cell appears to be the most common mechanism of phage resistance (Bohannon and Lenski, 2000), continued investigations into the diversity of phage receptors in *C. jejuni* is required to select the most efficient combinations of phages for therapy.

## ACKNOWLEDGMENTS

We are grateful to B. Wren for the gift of the *C. jejuni* NCTC11168 *kpsM* mutant. We sincerely appreciate the expert technical assistance of Lisbeth Schade Hansen, Christel Galschiøt Buerholt, Mark Miskolzie, David Simpson, Yasmin Barre, Cory Wenzel, Abofu Alemka, and Denis Arutyunov. This work was funded by a grant from the FOOD Research School at the Faculty of Life Sciences, University of Copenhagen, Denmark. Lieke B. van Alphen holds an Alberta Innovates Health Solutions (AIHS) Postdoctoral Fellowship, Shauna M. Crowley holds an AIHS Graduate Scholarship and Christine M. Szymanski holds an Alberta Innovates Scholar Award.

## REFERENCES

- Bacon, D. J., Szymanski, C. M., Burr, D. H., Silver, R. P., Alm, R. A., and Guerry, P. (2001). A phase-variable capsule is involved in virulence of *Campylobacter jejuni* 81-176. *Mol. Microbiol.* 40, 769–777.
- Bohannon, B. J. M., and Lenski, R. E. (2000). Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage. *Ecol. Lett.* 3, 362–377.
- Brüssow, H., and Hendrix, R. W. (2002). Phage genomics: small is beautiful. *Cell* 108, 13–16.
- Carrillo, C. D., Taboada, E., Nash, J. H., Lanthier, P., Kelly, J., Lau, P. C., Verhulp, R., Mykytczuk, O., Sy, J., Findlay, W. A., Amoako, K., Gomis, S., Willson, P., Austin, J. W., Potter, A., Babiuk, L., Allan, B., and Szymanski, C. M. (2004). Genome-wide expression analyses of *Campylobacter jejuni* NCTC11168 reveals coordinate regulation of motility and virulence by *flhA*. *J. Biol. Chem.* 279, 20327–20338.
- Chen, Y. H., Poly, F., Pakulski, Z., Guerry, P., and Monteiro, M. A. (2008). The chemical structure and genetic locus of *Campylobacter jejuni* CG8486 (serotype HS:4) capsular polysaccharide: the identification of 6-deoxy-D-idoheptopyranose. *Carbohydr. Res.* 343, 1034–1040.
- Comstock, L. E., and Kasper, D. L. (2006). Bacterial glycans: key mediators of diverse host immune responses. *Cell* 126, 847–850.
- Connerton, P. L., Loc Carrillo, C. M., Swift, C., Dillon, E., Scott, A., Rees, C. E., Dodd, C. E., Frost, J., and Connerton, I. F. (2004). Longitudinal study of *Campylobacter jejuni* bacteriophages and their hosts from broiler chickens. *Appl. Environ. Microbiol.* 70, 3877–3883.
- Coward, C., Grant, A. J., Swift, C., Philp, J., Towler, R., Heydarian, M., Frost, J. A., and Maskell, D. J. (2006). Phase-variable surface structures are required for infection of *Campylobacter jejuni* by bacteriophages. *Appl. Environ. Microbiol.* 72, 4638–4647.
- Doulatov, S., Hodes, A., Dai, L., Mandhana, N., Liu, M., Deora, R., Simons, R. W., Zimmerly, S., and Miller, J. F. (2004). Tropism switching in *Bordetella* bacteriophage defines a family of diversity-generating retroelements. *Nature* 431, 476–481.
- Drexler, K., Dannull, J., Hindennach, I., Mutschler, B., and Henning, U. (1991). Single mutations in a gene for a tail fiber component of an *Escherichia coli* phage can cause an extension from a protein to a carbohydrate as a receptor. *J. Mol. Biol.* 219, 655–663.
- Frost, J. A., Kramer, J. M., and Gillanders, S. A. (1999). Phage typing of *Campylobacter jejuni* and *Campylobacter coli* and its use as an adjunct to serotyping. *Epidemiol. Infect.* 123, 47–55.
- Gemski, P. Jr., Koeltzow, D. E., and Formal, S. B. (1975). Phage conversion of *Shigella flexneri* group antigens. *Infect. Immun.* 11, 685–691.
- Gemski, P. Jr., and Stocker, B. A. (1967). Transduction by bacteriophage P22 in nonsmooth mutants of *Salmonella typhimurium*. *J. Bacteriol.* 93, 1588–1597.
- Guerry, P., Poly, F., Riddle, M., Maue, A. C., Chen, Y.-H., and Monteiro, M. A. (2012). *Campylobacter* polysaccharide capsules: virulence and vaccines. *Front. Cell. Infect. Microbiol.* 2:7. doi:10.3389/fcimb.2012.00007
- Guerry, P., and Szymanski, C. M. (2008). *Campylobacter* sugars sticking out. *Trends Microbiol.* 16, 428–435.
- Hansen, V. M., Rosenquist, H., Baggesen, D. L., Brown, S., and Christensen, B. B. (2007). Characterization of *Campylobacter* phages including analysis of host range by selected *Campylobacter* Penner serotypes. *BMC Microbiol.* 7, 90. doi:10.1186/1471-2180-7-90
- Hashemolhosseini, S., Montag, D., Kramer, L., and Henning, U. (1994). Determinants of receptor specificity of coli phages of the T4 family: a chaperone alters the host range. *J. Mol. Biol.* 241, 524–533.
- Jones, M. A., Marston, K. L., Woodall, C. A., Maskell, D. J., Linton, D., Karlyshev, A. V., Dorrell, N., Wren, B. W., and Barrow, P. A. (2004). Adaptation of *Campylobacter jejuni* NCTC11168 to high-level colonization of the avian gastrointestinal tract. *Infect. Immun.* 72, 3769–3776.
- Karlyshev, A. V., Champion, O. L., Churcher, C., Brisson, J. R., Jarrell, H. C., Gilbert, M., Brochu, D., St. M. F., Li, J., Wakarchuk, W. W., Goodhead, I., Sanders, M., Stevens, K., White, B., Parkhill, J., Wren, B. W., and Szymanski, C. M. (2005). Analysis of *Campylobacter jejuni* capsular loci reveals multiple mechanisms for the generation of structural diversity and the ability to form complex heptoses. *Mol. Microbiol.* 55, 90–103.

- Karlyshev, A. V., Linton, D., Gregson, N. A., Lastovica, A. J., and Wren, B. W. (2000). Genetic and biochemical evidence of a *Campylobacter jejuni* capsular polysaccharide that accounts for Penner serotype specificity. *Mol. Microbiol.* 35, 529–541.
- Kutateladze, M., and Adamia, R. (2010). Bacteriophages as potential new therapeutics to replace or supplement antibiotics. *Trends Biotechnol.* 12, 591–595.
- Levy, S. B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes, challenges and responses. *Nat. Med.* 10, S122–S129.
- Linton, D., Karlyshev, A. V., and Wren, B. W. (2001). Deciphering *Campylobacter jejuni* cell surface interactions from the genome sequence. *Curr. Opin. Microbiol.* 4, 35–40.
- Liu, M., Deora, R., Doulatov, S. R., Gingery, M., Eiserling, F. A., Preston, A., Maskell, D. J., Simons, R. W., Cotter, P. A., Parkhill, J., and Miller, J. F. (2002). Reverse transcriptase-mediated tropism switching in *Bordetella* bacteriophage. *Science* 295, 2091–2094.
- McNally, D. J., Jarrell, H. C., Li, J., Khieu, N. H., Vinogradov, E., Szymanski, C. M., and Brisson, J. R. (2005). The HS:1 serostrain of *Campylobacter jejuni* has a complex teichoic acid-like capsular polysaccharide with nonstoichiometric fructofuranose branches and O-methyl phosphoramidate groups. *FEBS J.* 272, 4407–4422.
- McNally, D. J., Lamoureux, M. P., Karlyshev, A. V., Fiori, L. M., Li, J., Thacker, G., Coleman, R. A., Khieu, N. H., Wren, B. W., Brisson, J. R., Jarrell, H. C., and Szymanski, C. M. (2007). Commonality and biosynthesis of the O-methyl phosphoramidate capsule modification in *Campylobacter jejuni*. *J. Biol. Chem.* 282, 28566–28576.
- Montag, D., Hashemolhosseini, S., and Henning, U. (1990). Receptor-recognizing proteins of T-even type bacteriophages. The receptor-recognizing area of proteins 37 of phages T4 Tula and Tulb. *J. Mol. Biol.* 216, 327–334.
- Morona, R., Klose, M., and Henning, U. (1984). *Escherichia coli* K-12 outer membrane protein (OmpA) as a bacteriophage receptor: analysis of mutant genes expressing altered proteins. *J. Bacteriol.* 159, 570–578.
- Nordstrom, K., and Forsgren, A. (1974). Effect of protein A on adsorption of bacteriophages to *Staphylococcus aureus*. *J. Virol.* 14, 198–202.
- Parkhill, J., Wren, B. W., Mungall, K., Ketley, J. M., Churcher, C., Basham, D., Chillingworth, T., Davies, R. M., Feltwell, T., Holroyd, S., Jagels, K., Karlyshev, A. V., Moule, S., Pallen, M. J., Penn, C. W., Quail, M. A., Rajandream, M. A., Rutherford, K. M., van Vliet, A. H., Whitehead, S., and Barrell, B. G. (2000). The genome sequence of the food-borne pathogen *Campylobacter jejuni* reveals hyper-variable sequences. *Nature* 403, 665–668.
- Rakhuba, D. V., Kolomiets, E. I., Szwajcer Dey, E., and Novik, G. I. (2010). Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. *Pol. J. Microbiol.* 59, 145–155.
- Riede, I., and Eschbach, M. L. (1986). Evidence that TraT interacts with OmpA of *Escherichia coli*. *FEBS Lett.* 205, 241–245.
- Roberts, I. S. (1996). The biochemistry and genetics of capsular polysaccharide production in bacteria. *Annu. Rev. Microbiol.* 50, 285–315.
- Sails, A. D., Wareing, D. R., Bolton, F. J., Fox, A. J., and Curry, A. (1998). Characterisation of 16 *Campylobacter jejuni* and *C. coli* typing bacteriophages. *J. Med. Microbiol.* 47, 123–128.
- Scholl, D., Rogers, S., Adhya, S., and Merrill, C. R. (2001). Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of *Escherichia coli*. *J. Virol.* 75, 2509–2515.
- Scott, A. E., Timms, A. R., Connerton, P. L., Loc Carrillo, C., Adzfa Radzum, K., and Connerton, I. F. (2007). Genome dynamics of *Campylobacter jejuni* in response to bacteriophage predation. *PLoS Pathog.* 3, e119. doi:10.1371/journal.ppat.0030119
- Sørensen, M. C., van Alphen, L. B., Harboe, A., Li, J., Christensen, B. B., Szymanski, C. M., and Brøndsted, L. (2011). The F336 bacteriophage recognizes the capsular phosphoramidate modification of *Campylobacter jejuni* NCTC11168. *J. Bacteriol.* 193, 6742–6749.
- St Michael, F. S., Szymanski, C. M., Li, J., Chan, K. H., Khieu, N. H., Larocque, S., Wakarchuk, W. W., Brisson, J. R., and Monteiro, M. A. (2002). The structures of the lipooligosaccharide and capsule polysaccharide of *Campylobacter jejuni* genome sequenced strain NCTC 11168. *Eur. J. Biochem.* 269, 5119–5136.
- Stirm, S., and Freund-Molbert, E. (1971). *Escherichia coli* capsule bacteriophages. II. Morphology. *J. Virol.* 8, 330–342.
- Szymanski, C. M., Michael, F. S., Jarrell, H. C., Li, J., Gilbert, M., Larocque, S., Vinogradov, E., and Brisson, J. R. (2003). Detection of conserved N-linked glycans and phase-variable lipooligosaccharides and capsules from *Campylobacter* cells by mass spectrometry and high resolution magic angle spinning NMR spectroscopy. *J. Biol. Chem.* 278, 24509–24520.
- Timms, A. R., Cambray-Young, J., Scott, A. E., Petty, N. K., Connerton, P. L., Clarke, L., Seeger, K., Quail, M., Cummings, N., Maskell, D. J., Thomson, N. R., and Connerton, I. F. (2010). Evidence for a lineage of virulent bacteriophages that target *Campylobacter*. *BMC Genomics* 11, 214. doi:10.1186/1471-2164-11-214
- Weinbauer, M. G. (2004). Ecology of prokaryotic viruses. *FEMS Microbiol. Rev.* 28, 127–181.
- Yu, F., and Mizushima, S. (1982). Roles of lipopolysaccharide and outer membrane protein OmpC of *Escherichia coli* K-12 in the receptor function for bacteriophage T4. *J. Bacteriol.* 151, 718–722.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 02 November 2011; accepted: 30 January 2012; published online: 20 February 2012.

Citation: Sørensen MCH, van Alphen LB, Fodor C, Crowley SM, Christensen BB, Szymanski CM and Brøndsted L (2012) Phase variable expression of capsular polysaccharide modifications allows *Campylobacter jejuni* to avoid bacteriophage infection in chickens. *Front. Cell. Inf. Microbio.* 2:11. doi: 10.3389/fcimb.2012.00011

Copyright © 2012 Sørensen, van Alphen, Fodor, Crowley, Christensen, Szymanski and Brøndsted. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.